Original news and analysis on international IP policy
Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.
A new book and website examine the impact of intellectual property rights on access to new essential medicines and call for measures that were used to reduce prices of patented HIV medicines to be applied in the case of essential medicines.
The Modern Poland Foundation is pleased to launch an Open Call for Speakers at the 5th International CopyCamp Conference (October 27-28, 2016 in Warsaw).
Today the Medicines Patent Pool announced the signing of nine new sub-licensing agreements for the generic manufacturing of key HIV and hepatitis C treatments.
A new book provides ways for public research to avoid legal battles over genetic resources in the fields of agriculture, biomedicine, environmental management and microbiology by making best use of an international protocol on access to genetic resources and benefit-sharing.
European Commission President Jean-Claude Juncker said today that the European Union would not include national parliaments of EU member states in the final decision on the Canada-EU Trade Agreement (CETA). Juncker's CETA statement was made during the post-Brexit meeting of EU heads of state in Brussels today (28 June), several German newspapers reported quoting the German News Agency (DPA).
The World Health Organization has named veteran health crisis expert Peter Salama of Australia the next head of the Health Emergencies Programme, a high-profile position for the UN agency's leadership against outbreaks and disasters.
A new response plan for a strategic response to the Zika virus has been announced by the World Health Organization and the Pan American Health Organization.
The 28 European Union member governments have concluded next steps for addressing antimicrobial resistance, with a strong emphasis on reducing use of antibiotics in animals, but also including a call for new business models.
Doors to a global medical harmonisation organisation opened to the generic and biosimilar industry, which described it as an historical moment for them. The industry will now be able to sit on the assembly of the international body that joins regulators with the pharmaceutical industry.